PSNP1
MCID: SPR098
MIFTS: 56

Supranuclear Palsy, Progressive (PSNP1) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Supranuclear Palsy, Progressive

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 27GTR, 30ICD10, 31ICD10 via Orphanet, 37MedGen, 38MedlinePlus, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 49NINDS, 50Novoseek, 52OMIM, 54Orphanet, 62SNOMED-CT, 64The Human Phenotype Ontology, 68UMLS, 69UMLS via Orphanet, 70UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Supranuclear Palsy, Progressive:

Name: Supranuclear Palsy, Progressive 52 48 25 12 39
Progressive Supranuclear Palsy 11 48 25 49 54 38 13 68
Steele-Richardson-Olszewski Syndrome 11 48 25 49 70
Progressive Supranuclear Ophthalmoplegia 11 25 27
Psp 48 25 70
Familial Progressive Supranuclear Palsy 48 68
 
Progressive Supranuclear Palsy 1 70
Supranuclear Palsy Progressive 50
Richardson's Syndrome 25
Psp Syndrome 54
Psnp1 70

Characteristics:

Orphanet epidemiological data:

54
progressive supranuclear palsy:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (United States),1-9/100000 (Italy),1-5/10000 (Guadeloupe),1-9/100000 (United Kingdom),1-9/1000000 (Libyan Arab Jamahiriya),1-9/1000000 (United States),1-9/1000000 (Australia); Age of onset: Adult; Age of death: elderly

HPO:

64
supranuclear palsy, progressive:
Inheritance: autosomal dominant inheritance, heterogeneous
Onset and clinical course: adult onset

Classifications:



External Ids:

OMIM52 601104
Disease Ontology11 DOID:678
ICD1030 G23.1
MeSH39 D013494
NCIt45 C85028
Orphanet54 ORPHA683
ICD10 via Orphanet31 G23.1
MESH via Orphanet40 D013494
UMLS via Orphanet69 C0038868
MedGen37 C0038868

Summaries for Supranuclear Palsy, Progressive

About this section
OMIM:52 Progressive supranuclear palsy (PSP) is the second most frequent cause of degenerative parkinsonism. In addition to... (601104) more...

MalaCards based summary: Supranuclear Palsy, Progressive, also known as progressive supranuclear palsy, is related to supranuclear palsy, progressive atypical and progressive supranuclear palsy-corticobasal syndrome, and has symptoms including back pain, back pain and headache. An important gene associated with Supranuclear Palsy, Progressive is MAPT (Microtubule Associated Protein Tau), and among its related pathways are Neurotransmitter Clearance In The Synaptic Cleft and Acetylcholine Synthesis. Affiliated tissues include brain and eye, and related mouse phenotypes are taste/olfaction and respiratory system.

NIH Rare Diseases:48 Progressive supranuclear palsy (psp) is a degenerative neurologic disease due to damage to nerve cells in the brain. signs and symptoms vary but may include loss of balance; blurring of vision; problems controlling eye movement; changes in mood, behavior and judgment; cognitive decline; and slowing and slurred speech. psp is often misdiagnosed as parkinson disease due to similar symptoms. onset is usually after age 60 but may occur earlier. most cases of psp appear to be sporadic, but familial cases have been reported. some cases have been found to be caused by a mutation in the mapt gene, and other genetic factors are being studied. there is currently no effective treatment for psp, and symptoms usually do not respond to medications. research regarding potential treatments is ongoing. last updated: 1/28/2016

UniProtKB/Swiss-Prot:70 Progressive supranuclear palsy 1: Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.

MedlinePlus:38 Progressive supranuclear palsy (psp) is a rare brain disease. it affects brain cells that control the movement of your eyes. this leads to serious and permanent problems with balance and the way you walk. it usually occurs in middle-aged or elderly people. symptoms are very different in each person, but may include personality changes, speech, vision and swallowing problems. doctors sometimes confuse psp with parkinson's disease or alzheimer's disease. psp has no cure and no effective treatments. walking aids, special glasses and certain medicines might help somewhat. although the disease gets worse over time, it isn't fatal on its own. however, psp is dangerous because it increases your risk of pneumonia and choking from swallowing problems and injuries from falling. nih: national institute of neurological disorders and stroke

NINDS:49 Progressive supranuclear palsy (PSP) is a rare brain disorder that causes serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. One of the classic signs of the disease is an inability to aim the eyes properly, which occurs because of lesions in the area of the brain that coordinates eye movements. Some individuals describe this effect as a blurring. Affected individuals often show alterations of mood and behavior, including depression and apathy as well as progressive mild dementia.

Genetics Home Reference:25 Progressive supranuclear palsy is a brain disorder that affects movement, vision, speech, and thinking ability (cognition). The signs and symptoms of this disorder usually become apparent in mid- to late adulthood, most often in a person's 60s. Most people with progressive supranuclear palsy survive 5 to 9 years after the disease first appears, although a few affected individuals have lived for more than a decade.

Disease Ontology:11 A movement disease characterized by serious and progressive problems with control of gait and balance, along with complex eye movement and thinking problems. It involves gradual deterioration and death of specific volumes of the brain.

Wikipedia:71 Progressive supranuclear palsy (PSP; or the Steele-Richardson-Olszewski syndrome, after the doctors who... more...

Related Diseases for Supranuclear Palsy, Progressive

About this section

Diseases in the Supranuclear Palsy, Progressive family:

Supranuclear Palsy, Progressive, 2 Supranuclear Palsy, Progressive, 3
Progressive Supranuclear Palsy, Mapt-Related

Diseases related to Supranuclear Palsy, Progressive via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 74)
idRelated DiseaseScoreTop Affiliating Genes
1supranuclear palsy, progressive atypical12.2
2progressive supranuclear palsy-corticobasal syndrome12.2
3supranuclear palsy, progressive, 212.1
4supranuclear palsy, progressive, 312.1
5classic progressive supranuclear palsy syndrome12.1
6progressive supranuclear palsy-progressive non-fluent aphasia syndrome12.1
7pneumothorax, primary spontaneous11.5
8keratosis palmoplantaris striata10.3APOE, MAPT
9scrotum basal cell carcinoma10.2MAPT, SLC6A3
10riedel's fibrosing thyroiditis10.2LRRK2, MAPT, SNCA
11deafness, autosomal recessive 10110.2MAPT, RPS27A, SNCA
12cyprus facial neuromusculoskeletal syndrome10.2MAPT, RPS27A, SNCA
13ceroid lipofuscinosis, neuronal, 110.2LRRK2, PARK7, SNCA
14lethal congenital contracture syndrome 810.2LRRK2, PARK7, SNCA
15multiple system atrophy10.2PARK7, SNCA
16parkinson disease 6, early onset10.2LRRK2, PARK7
17thyrotropin-releasing hormone deficiency10.2LRRK2, SLC6A3, SNCA
18thrombosis10.2LRRK2, PARK7, SNCA
19trichothiodystrophy 3, photosensitive10.1LRRK2, PARK7, SNCA
20transient neonatal myasthenia gravis10.1LRRK2, SNCA
21cystic echinococcosis10.1CHAT, RPS27A, SNCA
22proteus syndrome, somatic10.1RPS27A, SLC6A3, SNCA
23benign partial epilepsy with secondarily generalized seizures in infancy10.1LRRK2, MAPT, SLC6A3, SNCA
24juvenile amyotrophic lateral sclerosis with dementia10.1APP, MAPT, SNCA
25atrial septal defect 910.1APP, MAPT, SNCA
26immune-mediated encephalomyelitis10.1APOE, CHAT
27meckel syndrome 1010.1APOE, APP, MAPT
28spink1-related hereditary pancreatitis10.1LRRK2, MAPT, PARK7, SNCA
29protein r deficiency10.1GRN, MAPT
30plekhm1-related autosomal recessive osteopetrosis10.1LRRK2, MAPT, PARK7, SNCA
31gata1-related thrombocytopenia10.1GRN, MAPT
32hereditary paraganglioma-pheochromocytoma syndromes10.0GRN, MAPT
33ichthyosis lamellar 210.0APOE, APP, MAPT
34hard palate cancer10.0APOE, APP, SNCA
35femoral neuropathy10.0GRN, MAPT, SLC6A3
36pythiosis10.0ACHE, SNCA, TH
37allergic bronchopulmonary aspergillosis, familial10.0APOE, APP, MAPT, RPS27A
38andersen syndrome10.0GRN, MAPT, RPS27A
39bone dysplasia azouz type9.9ACHE, APOE, APP, MAPT
40acne inversa, familial, 39.9APOE, CHAT, MAPT, RPS27A, SNCA
41klippel-feil syndrome 4, autosomal recessive, with myopathy and facial dysmorphism9.9LRRK2, PARK7, SNCA, TH
42lower gum cancer9.9ACHE, LRRK2, RPS27A, SLC6A3, SNCA
43kashin-beck disease9.9ACHE, CHAT, TH
44hypoparathyroidism-intellectual disability-dysmorphism syndrome9.9ACHE, TH
45ovarian mucinous adenocarcinoma9.9ACHE, SLC6A3, SNCA, TH
46severe congenital nemaline myopathy9.9APOE, GRN, MAPT, RPS27A
47postauricular lymphadenitis9.9CBS, GRN, MAPT
48pancreatic solid pseudopapillary carcinoma9.9CBS, GRN, MAPT
49mucopolysaccharidosis iv9.8GRN, MAPT, RPS27A
50cerebroretinal vasculopathy9.8GRN, MAPT

Graphical network of the top 20 diseases related to Supranuclear Palsy, Progressive:



Diseases related to supranuclear palsy, progressive

Symptoms & Phenotypes for Supranuclear Palsy, Progressive

About this section

Symptoms by clinical synopsis from OMIM:

601104

Clinical features from OMIM:

601104

Human phenotypes related to Supranuclear Palsy, Progressive:

 54 64 (show all 44)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 supranuclear gaze palsy64 54 Very frequent (99-80%) HP:0000605
2 supranuclear ophthalmoplegia64 54 Very frequent (99-80%) HP:0000623
3 dysphagia64 54 Very frequent (99-80%) HP:0002015
4 postural instability64 54 Very frequent (99-80%) HP:0002172
5 unsteady gait64 54 Very frequent (99-80%) HP:0002317
6 falls64 54 Very frequent (99-80%) HP:0002527
7 neuronal loss in central nervous system64 54 Very frequent (99-80%) HP:0002529
8 abnormal synaptic transmission64 54 Very frequent (99-80%) HP:0012535
9 impulsivity64 54 Very frequent (99-80%) HP:0100710
10 vertical supranuclear gaze palsy64 54 Frequent (79-30%) HP:0000511
11 slow saccadic eye movements64 54 Frequent (79-30%) HP:0000514
12 blepharospasm64 54 Frequent (79-30%) HP:0000643
13 depression64 54 Frequent (79-30%) HP:0000716
14 delayed speech and language development64 54 Frequent (79-30%) HP:0000750
15 dystonia54 Frequent (79-30%)
16 bradykinesia64 54 Frequent (79-30%) HP:0002067
17 cerebral cortical atrophy64 54 Frequent (79-30%) HP:0002120
18 gliosis64 54 Frequent (79-30%) HP:0002171
19 pseudobulbar signs64 54 Frequent (79-30%) HP:0002200
20 memory impairment64 54 Frequent (79-30%) HP:0002354
21 aphasia64 54 Frequent (79-30%) HP:0002381
22 cognitive impairment54 Frequent (79-30%)
23 abnormality of eye movement54 Occasional (29-5%)
24 dementia64 54 Occasional (29-5%) HP:0000726
25 tremor64 54 Occasional (29-5%) HP:0001337
26 rigidity64 54 Occasional (29-5%) HP:0002063
27 photophobia64 HP:0000613
28 blurred vision64 HP:0000622
29 diplopia64 HP:0000651
30 eyelid apraxia64 HP:0000658
31 irritability64 HP:0000737
32 apathy64 HP:0000741
33 frontal release signs64 HP:0000743
34 dysarthria64 HP:0001260
35 parkinsonism64 HP:0001300
36 gait imbalance64 HP:0002141
37 neurofibrillary tangles64 HP:0002185
38 mutism64 HP:0002300
39 akinesia64 HP:0002304
40 frontolimbic dementia64 HP:0002439
41 limb dystonia64 HP:0002451
42 granulovacuolar degeneration64 HP:0002528
43 axial dystonia64 HP:0002530
44 retrocollis64 HP:0002544

UMLS symptoms related to Supranuclear Palsy, Progressive:


back pain, headache, muscle rigidity, ophthalmoplegia, pain, sciatica, seizures, syncope, tremor, photophobia, chronic pain, bradykinesia, blurred vision, poor mobility, vertigo/dizziness, forgetful, sleeplessness

MGI Mouse Phenotypes related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

41 (show all 11)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000539410.2APOE, MAPT, SLC6A3, SNCA
2MP:00053889.1ACHE, APOE, CHAT, CRHR1, LRRK2, TH
3MP:00107718.7APOE, APP, LRRK2, MAPT, SLC6A3, SNCA
4MP:00028738.2APP, CHAT, CRHR1, LRRK2, MAPT, SLC6A3
5MP:00053917.7ACHE, APOE, CHAT, CRHR1, GRN, MAPT
6MP:00053847.7APOE, APP, GRN, LRRK2, MAPT, PARK7
7MP:00030127.6ACHE, APOE, APP, CRHR1, GRN, LRRK2
8MP:00107687.0ACHE, APOE, APP, CHAT, CRHR1, GRN
9MP:00053866.7ACHE, APOE, APP, CHAT, CRHR1, GRN
10MP:00053766.6ACHE, APOE, APP, CHAT, CRHR1, GRN
11MP:00036316.6ACHE, APOE, APP, CHAT, CRHR1, GRN

Drugs & Therapeutics for Supranuclear Palsy, Progressive

About this section

Drugs for Supranuclear Palsy, Progressive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 85)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Rivastigmineapproved, investigationalPhase 3, Phase 283123441-03-277991
Synonyms:
(S)-3-(1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
123441-03-2
3-((1S)-1-(Dimethylamino)ethyl)phenyl N-ethyl-N-methylcarbamate
3-((1S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate
AB1004572
AC1L2U92
BIDD:GT0316
C11766
CHEMBL636
CID77991
Carbamic acid, N-ethyl-N-methyl-, 3-[(1S)-1-(dimethylamino)ethyl]phenyl ester
Carbamic acid, ethylmethyl-, 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
D03822
DB00989
ENA 713 free base
 
Ena 713 Free Base
Ethylmethylcarbamic acid 3-((1S)-1-(dimethylamino)ethyl)phenyl ester
Exelon
Exelon Patch
HMS2089H18
I06-2037
LS-172571
MolPort-003-666-662
NCGC00167531-01
Rivastigmine (JAN/USAN/INN)
Rivastigmine Hydrogen Tartrate
Rivastigmine [USAN:INN]
Rivastigmine hydrogen tartrate
SDZ 212-713
UNII-PKI06M3IW0
[3-[(1S)-1-(dimethylamino)ethyl]phenyl] N-ethyl-N-methylcarbamate
m-((S)-1-(Dimethylamino)ethyl)phenyl ethylmethylcarbamate
rivastigmine
2
Minocyclineapproved, investigationalPhase 323110118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
Alti-Minocycline
Apo-Minocycline
Arestin
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
Dynacin
Gen-Minocycline
HMS2090D03
HSDB 3130
Klinomycin
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline HCl
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
Minocyn
Minomycin
NCGC00178854-01
NSC 141993
NSC141993
Novo-Minocycline
Solodyn
UNII-FYY3R43WGO
Vectrin
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
3
Riluzoleapproved, investigationalPhase 3651744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
4
RasagilineapprovedPhase 354136236-51-63052776
Synonyms:
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine
(1R)-N-Propargylindan-1-amine
(1R)-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine
(R)-Indan-1-yl-prop-2-ynyl-amine
(R)-N-2-Propynyl-1-indanamine
136236-51-6
1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)
AC-723
AC1MHJZT
Azilect
Azilect (TN)
CHEBI:45357
 
CHEMBL887
CID3052776
D08469
DB01367
LS-186771
LS-187776
MolPort-003-850-132
NCGC00168774-01
RAS
Rasagiline (INN)
Rasagiline [INN]
UNII-003N66TS6T
ZINC19875504
rasagiline
5Cholinesterase InhibitorsPhase 3, Phase 2592
6Protective AgentsPhase 3, Phase 2, Phase 17443
7Cholinergic AgentsPhase 3, Phase 23992
8Neuroprotective AgentsPhase 3, Phase 21716
9Neurotransmitter AgentsPhase 3, Phase 218340
10Trace ElementsPhase 2, Phase 3, Phase 16001
11Anti-Infective AgentsPhase 322062
12MicronutrientsPhase 2, Phase 3, Phase 16001
13UbiquinonePhase 2, Phase 3145
14AnticonvulsantsPhase 3, Phase 22695
15VitaminsPhase 2, Phase 3, Phase 15282
16Anti-Bacterial AgentsPhase 311226
17Excitatory Amino Acid AntagonistsPhase 31347
18Excitatory Amino AcidsPhase 31362
19
Coenzyme Q10experimental, NutraceuticalPhase 2, Phase 3121303-98-05281915
Synonyms:
(all-E)-2,3-dimethoxy-5-methyl-6-(3,7,11,15,19,23,27,31-octamethyl-2,6,10,14,18,22,26,30-dotriacontaoctaenyl)-2,5-Cyclohexadiene-1,4-dione
(all-E)-2-(3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-2,5-Cyclohexadiene-1,4-dione
2-(3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl)-5,6-dimethoxy-3-methyl-p-Benzoquinone
2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-Decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaenyl]-5,6-dimethoxy-3-methyl- 2,5-Cyclohexadiene-1,4-dione
4-Ethyl-5-fluoropyrimidine
Aqua Q 10L10
Aqua Q10
Bio-Quinon
Bio-Quinone Q10
CoQ10
Coenzyme Q-10
Coenzyme Q10
Ensorb
Kaneka Q10
 
Kudesan
Li-Q-Sorb
Liquid-Q
Neuquinon
Neuquinone
PureSorb Q 40
Q 10AA
Q-Gel
Q-Gel 100
Ubidecarenone
Ubiquinone 10
Ubiquinone 50
Ubiquinone Q10
Ubiquinone-10
Unbiquinone
Unispheres Q 10
20
DonepezilapprovedPhase 2286120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
21
Valproic Acidapproved, investigationalPhase 232799-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
22
Acetylcarnitineapproved, investigationalPhase 1, Phase 2443040-38-81
Synonyms:
(+-)-Acetylcarnitine
(-)-Acetylcarnitine
(R)-Acetylcarnitine
ALCAR
Acetyl-L-(-)-carnitine
Acetyl-L-carnitine
Acetyl-carnitine
Acetylcarnitine
 
L-Acetylcarnitine
L-Carnitine acetyl ester
L-O-Acetylcarnitine
Levocarnitine acetyl
Nicetile
O-Acetyl-L-carnitine
O-Acetylcarnitine
O-acetyl-L-carnitine
acetyl-L-carnitine
23
Folic Acidapproved, nutraceutical, vet_approvedPhase 1, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
24Nootropic AgentsPhase 2, Phase 1716
25AnestheticsPhase 1, Phase 29596
26Pharmaceutical SolutionsPhase 1, Phase 28192
27Fluorodeoxyglucose F18Phase 2412
28Thioctic AcidPhase 1, Phase 2118
29Lithium carbonatePhase 1, Phase 2240554-13-2
30Vitamin B ComplexPhase 1, Phase 24337
31Central Nervous System DepressantsPhase 2, Phase 113403
32RadiopharmaceuticalsPhase 2, Early Phase 1514
33Psychotropic DrugsPhase 2, Phase 16430
34GABA AgentsPhase 21684
35Tranquilizing AgentsPhase 2, Phase 14265
36Antimanic AgentsPhase 2, Phase 1814
37Antidepressive AgentsPhase 1, Phase 22736
38AntioxidantsPhase 1, Phase 23050
39carnitineNutraceuticalPhase 1, Phase 2162
40Alpha-lipoic AcidNutraceuticalPhase 1, Phase 2118
41FolateNutraceuticalPhase 1, Phase 24392
42Vitamin B9NutraceuticalPhase 1, Phase 24392
43
DopamineapprovedPhase 1383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
44
Benzoic AcidapprovedPhase 1865-85-0243
Synonyms:
Benzenecarboxylate
Benzenecarboxylic acid
Benzeneformate
Benzeneformic acid
Benzenemethanoate
Benzenemethanoic acid
Benzenemethonic acid
Benzoate
Benzoic acid
Benzoic acid sodium salt
 
Carboxybenzene
Diacylate
Diacylic acid
Dracylate
Dracylic acid
Oracylic acid
Phenylcarboxylate
Phenylcarboxylic acid
Phenylformate
Phenylformic acid
Sodium benzoate
Sodium benzoic acid
45
Salicylic acidapproved, vet_approvedPhase 118969-72-7338
Synonyms:
105910_ALDRICH
105910_SIAL
2 Hydroxybenzoic Acid
2-Carboxyphenol
2-Hydroxybenzenecarboxylate
2-Hydroxybenzenecarboxylic acid
2-Hydroxybenzoate
2-Hydroxybenzoic acid
2-hydroxy(1-14c)benzoic acid
247588_SIAL
27301_SIAL
69-72-7
7681-06-3
8052-31-1
84210_FLUKA
84210_SIAL
AB1002436
AC1L190M
AC1Q1HCK
AC1Q72IF
AI3-02407
AKOS000118979
ALPHA/BETA HYDROXY ACIDS (SALICYLIC ACID) (SEE ALPHA/BETA HYDROXY ACIDS)
AR-1E2203
ATA fraction 10, ammonium salt
Acid, 2-Hydroxybenzoic
Acid, Salicylic
Acid, o-Hydroxybenzoic
Acid, ortho-Hydroxybenzoic
Acido o-idrossibenzoico
Acido o-idrossibenzoico [Italian]
Acido salicilico
Acido salicilico [Italian]
Acidum salicylicum
Advanced Pain Relief Callus Removers
Advanced Pain Relief Corn Removers
Advanced pain relief callus removers
Advanced pain relief corn removers
Akurza Cream
Akurza Lotion
Alpha/Beta Hydroxy Acids (Glycolic Acid, Salicylic Acid)
BENZOIC ACID,2-HYDROXY SALICYLIC ACID
BIDD:ER0602
BRN 0774890
Benzoic acid, 2-hydroxy- (9CI)
C00805
CCRIS 6714
CHEBI:16914
CHEMBL424
CID338
CMC_13852
Caswell No. 731
Clear away Wart Remover
Clear away wart remover
Compound W
Compound w
D00097
D020156
DB00936
DHS Sal Shampoo
DivK1c_000301
Domerine
Dr. Scholl'S Callus Removers
Dr. Scholl'S Corn Removers
Dr. Scholl'S Wart Remover Kit
Dr. Scholl's callus removers
Dr. Scholl's corn removers
Dr. Scholl's wart remover kit
DuoPlant Gel
Duofil Wart Remover
Duofil wart remover
Duofilm
Duoplant
E9A559BE-383B-4F83-BC02-3031D03D558A
EINECS 200-712-3
EPA Pesticide Chemical Code 076602
Freezone
H0206
HSDB 672
Hydrisalic Gel
I04-0192
IDI1_000301
InChI=1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10
Ionil
Ionil Plus
Ionil plus
Ionil-Plus
 
K 537
K 557
KBio1_000301
KBio2_001428
KBio2_003996
KBio2_006564
KBioSS_001428
Keralyt
Kyselina 2-hydroxybenzoova
Kyselina 2-hydroxybenzoova [Czech]
Kyselina salicylova
Kyselina salicylova [Czech]
LS-2169
MLS000069653
Mediplast pads
MolPort-001-769-476
NCGC00159447-02
NCGC00159447-04
NINDS_000301
NSC 180
NSC180
NSC629474
O-Carboxyphenol
O-Hydroxybenzoate
O-Hydroxybenzoic acid
O-carboxyphenol
O-hydroxybenzoic acid
Occlusal
Oprea1_040343
Orthohydroxybenzoic acid
P&S Shampoo
Phenol-2-carboxylate
Phenol-2-carboxylic acid
Propa pH Peel-Off Acne Mask
Psoriacid-S-Stift
Psoriacid-S-stift
Retarder SAX
Retarder W
Rutranex
S5922_SIGMA
S7401_SIGMA
S8519_SIGMA
SALICYLIC ACID (SEE ALSO ALPHA HYDROXY ACIDS)
SALICYLIC ACID, ACS
SAX
SBB052826
SGCUT00012
SMP2_000145
SMR000059163
STK258681
Salex Cream
Salex Lotion
Salicyclic acid
Salicylate
Salicylic acid
Salicylic acid & Sulfur Soap
Salicylic acid (6CI,8CI)
Salicylic acid (JP15/USP)
Salicylic acid (TN)
Salicylic acid Soap
Salicylic acid [USAN:JAN]
Salicylic acid collodion
Salicylic acid soap
Salicylic acid, tech
Salicylic acid, tech.
Salicylic acid-ring-UL-14C
Saligel
Salonil
Sebucare
Sebulex
Spectrum_000948
Stri-Dex
Trans-Ver-Sal
UNII-O414PZ4LPZ
UPCMLD-DP126
UPCMLD-DP126:001
Verrugon
W398500_ALDRICH
WLN: QVR BQ
bmse000252
o Hydroxybenzoic Acid
o-Carboxyphenol
o-hydroxybenzoic acid
ortho Hydroxybenzoic Acid
ortho-Hydroxybenzoic Acid
phenol derivative, 7
salicylate
salicylic acid
to_000004
46Dopamine AgentsPhase 13836
47Peripheral Nervous System AgentsPhase 123689
48SalicylatesPhase 1100
49Cyclooxygenase InhibitorsPhase 12870
50Salicylsalicylic acidPhase 127

Interventional clinical trials:

(show top 50)    (show all 78)
idNameStatusNCT IDPhase
1Validation of DaTscan for Detection of Parkinson Disease Related DisordersUnknown statusNCT02138682Phase 4
2Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear PalsyCompletedNCT01110720Phase 2, Phase 3
3Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)CompletedNCT00382824Phase 2, Phase 3
4Effects of Coenzyme Q10 in PSP and CBDCompletedNCT00532571Phase 2, Phase 3
5Study About Efficacy and Safety to Treat Multi-System-AtrophyCompletedNCT00146809Phase 3
6Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear PalsyRecruitingNCT02839642Phase 3
7Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear PalsyTerminatedNCT01187888Phase 3
8Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS)TerminatedNCT00211224Phase 3
9Study of the Distractibility Syndrome in Patients With Progressive Supranuclear PalsyUnknown statusNCT00139373Phase 2
10Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of ParkinsonismUnknown statusNCT01824121Phase 1, Phase 2
11Efficacy Study for Treatment of Dementia in Progressive Supranuclear PalsyUnknown statusNCT00522015Phase 2
12Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)CompletedNCT00385710Phase 2
13Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear PalsyCompletedNCT01537549Phase 1, Phase 2
14Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyCompletedNCT00328874Phase 2
15A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal DegenerationCompletedNCT00703677Phase 1, Phase 2
16Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear PalsyCompletedNCT00005903Phase 2
17The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission TomographyCompletedNCT01824056Phase 2
18A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear PalsyRecruitingNCT02985879Phase 2
19Study of BMS-986168 in Patients With Progressive Supranuclear PalsyRecruitingNCT03068468Phase 2
20Davunetide (AL-108) in Predicted Tauopathies - Pilot StudyActive, not recruitingNCT01056965Phase 2
21Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy VolunteersCompletedNCT02167594Phase 1
22Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy SubjectsCompletedNCT02103894Phase 1
23Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and MoodCompletedNCT02104401Phase 1
24Young Plasma Transfusions for Progressive Supranuclear PalsyRecruitingNCT02460731Phase 1
25A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear PalsyRecruitingNCT02422485Phase 1
26Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear PalsyActive, not recruitingNCT02494024Phase 1
27Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear PalsyActive, not recruitingNCT02460094Phase 1
28Safety Study of TPI-287 to Treat CBS and PSPActive, not recruitingNCT02133846Phase 1
29Extension Study of BMS-986168 in Patients With Progressive Supranuclear Palsy Who Participated in CN002003Enrolling by invitationNCT02658916Phase 1
30Postural Instability in Progressive Supranuclear PalsyUnknown statusNCT01563276
31Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.Unknown statusNCT01815281
32Robot Walking Rehabilitation in Parkinson's DiseaseUnknown statusNCT01668407
33Diagnostic and Prognostic Biomarkers in Parkinson DiseaseUnknown statusNCT00653783
34Innovative Biomarkers in Alzheimer's Disease and Frontotemporal Dementia (FTD): Preventative and PersonalizedUnknown statusNCT01403519
35The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other DementiasUnknown statusNCT01800214
36Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian SyndromesUnknown statusNCT00368199Early Phase 1
37Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyCompletedNCT01049399
38Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear PalsyCompletedNCT02734485
39Rehabilitation in Patients With Progressive Supranuclear PalsyCompletedNCT02109393
40Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and ControlsCompletedNCT01348061
41A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy.CompletedNCT00605930
42Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal DegenerationCompletedNCT01174771
43Risk Factors for Progressive Supranuclear Palsy (PSP)CompletedNCT00431301
442-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified ParkinsonismCompletedNCT02214862Early Phase 1
45Analysis of the Enteric Nervous System Using Colonic BiopsiesCompletedNCT01353183
46MRI Study of Brain Activity in Healthy Adults and Individuals With Parkinsonism and Rapid Eye Movement Disorder.CompletedNCT01547481
47Prefrontal Cortex and Abstract ThinkingCompletedNCT01100281
48Research of Biomarkers in Parkinson DiseaseCompletedNCT00465790Early Phase 1
49Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With TauopathiesCompletedNCT02531360Early Phase 1
50Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance ImagingCompletedNCT01715727

Search NIH Clinical Center for Supranuclear Palsy, Progressive


Cochrane evidence based reviews: supranuclear palsy, progressive

Genetic Tests for Supranuclear Palsy, Progressive

About this section

Genetic tests related to Supranuclear Palsy, Progressive:

id Genetic test Affiliating Genes
1 Progressive Supranuclear Ophthalmoplegia27

Anatomical Context for Supranuclear Palsy, Progressive

About this section

MalaCards organs/tissues related to Supranuclear Palsy, Progressive:

36
Brain, Eye

Publications for Supranuclear Palsy, Progressive

About this section

Variations for Supranuclear Palsy, Progressive

About this section

UniProtKB/Swiss-Prot genetic disease variations for Supranuclear Palsy, Progressive:

70
id Symbol AA change Variation ID SNP ID
1MAPTp.Arg5LeuVAR_019661rs63750959
2MAPTp.Gly620ValVAR_037439rs63751391

Clinvar genetic disease variations for Supranuclear Palsy, Progressive:

5
id Gene Variation Type Significance SNP ID Assembly Location
1MAPTNM_ 016835.4(MAPT): c.1853C> T (p.Pro618Leu)SNVPathogenicrs63751273GRCh37Chr 17, 44087755: 44087755
2MAPTNM_ 016835.4(MAPT): c.14G> T (p.Arg5Leu)SNVPathogenicrs63750959GRCh37Chr 17, 44039717: 44039717
3MAPTNM_ 016835.4(MAPT): c.2006C> T (p.Ser669Leu)SNVPathogenicrs63750425GRCh37Chr 17, 44096041: 44096041
4MAPTNM_ 016835.4(MAPT): c.1859G> T (p.Gly620Val)SNVPathogenicrs63751391GRCh37Chr 17, 44087761: 44087761

Expression for genes affiliated with Supranuclear Palsy, Progressive

About this section
Search GEO for disease gene expression data for Supranuclear Palsy, Progressive.

Pathways for genes affiliated with Supranuclear Palsy, Progressive

About this section

Pathways related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 11)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.8ACHE, SLC6A3
29.7ACHE, CHAT
3
Show member pathways
9.3ACHE, SLC6A3, TH
4
Show member pathways
9.2ACHE, CHAT, TH
59.2ACHE, CHAT, TH
69.2APOE, APP, MAPT
79.2APOE, APP, MAPT
89.1PARK7, SLC6A3, SNCA, TH
98.8LRRK2, PARK7, SLC6A3, SNCA, TH
107.8APOE, APP, LRRK2, MAPT, PARK7, SNCA
11
Show member pathways
7.5APOE, APP, LRRK2, MAPT, PARK7, SLC6A3

GO Terms for genes affiliated with Supranuclear Palsy, Progressive

About this section

Cellular components related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1inclusion bodyGO:001623410.7LRRK2, SNCA
2presynapseGO:009879310.1CHAT, PARK7, SLC6A3
3dendriteGO:00304259.9APOE, LRRK2, MAPT, TH
4synaptic vesicleGO:00080219.9LRRK2, SNCA, TH
5smooth endoplasmic reticulumGO:00057909.7APP, TH
6growth coneGO:00304269.6APP, LRRK2, MAPT, SNCA
7membrane raftGO:00451219.5APP, LRRK2, PARK7, SLC6A3
8neuronal cell bodyGO:00430259.3APOE, LRRK2, MAPT, SLC6A3, SNCA, TH
9neuron projectionGO:00430058.9APP, LRRK2, PARK7, SLC6A3, TH
10terminal boutonGO:00431958.6APP, LRRK2, SNCA, TH
11axonGO:00304248.5APP, LRRK2, MAPT, PARK7, SLC6A3, SNCA
12extracellular spaceGO:00056158.2ACHE, APOE, APP, GRN, LRRK2, RPS27A

Biological processes related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1microglial cell activationGO:000177410.7MAPT, SNCA
2intracellular distribution of mitochondriaGO:004831210.6LRRK2, MAPT
3positive regulation of endocytosisGO:004580710.6APOE, SNCA
4regulation of mitochondrial fissionGO:009014010.6LRRK2, MAPT
5regulation of locomotionGO:004001210.6LRRK2, SNCA
6regulation of neuronal synaptic plasticityGO:004816810.6APOE, SNCA
7regulation of neuron deathGO:190121410.5LRRK2, SNCA
8negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayGO:190223610.5LRRK2, PARK7
9negative regulation of hydrogen peroxide-induced cell deathGO:190320610.5LRRK2, PARK7
10amyloid precursor protein metabolic processGO:004298210.5ACHE, APOE
11supramolecular fiber organizationGO:009743510.5MAPT, SNCA
12cellular response to manganese ionGO:007128710.4LRRK2, TH
13dopamine uptake involved in synaptic transmissionGO:005158310.3PARK7, SLC6A3, SNCA
14cellular response to oxidative stressGO:003459910.3LRRK2, PARK7, SNCA
15negative regulation of neuron apoptotic processGO:004352410.3APOE, PARK7, SNCA
16negative regulation of protein phosphorylationGO:000193310.2LRRK2, PARK7, SNCA
17dopamine biosynthetic processGO:004241610.1SLC6A3, SNCA, TH
18amyloid fibril formationGO:199000010.1APP, MAPT
19negative regulation of neuron deathGO:190121510.0APOE, LRRK2, PARK7, SNCA
20virion assemblyGO:00190689.9APOE, RPS27A
21mating behaviorGO:00076179.8APP, TH
22adult locomotory behaviorGO:00083449.8APP, PARK7, SNCA
23synaptic transmission, dopaminergicGO:00019639.6PARK7, SNCA, TH
24response to oxidative stressGO:00069799.6APOE, APP, LRRK2
25synapse organizationGO:00508089.6APP, MAPT, SNCA
26locomotory behaviorGO:00076269.5APP, SLC6A3, TH
27neurotransmitter biosynthetic processGO:00421369.5ACHE, CHAT, SLC6A3, TH
28cellular protein metabolic processGO:00442679.5APOE, APP, RPS27A, SNCA

Molecular functions related to Supranuclear Palsy, Progressive according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1lipoprotein particle bindingGO:007181310.7APOE, MAPT
2cuprous ion bindingGO:190313610.6PARK7, SNCA
3dopamine bindingGO:003524010.4SLC6A3, TH
4ferrous iron bindingGO:000819810.4SNCA, TH
5protein phosphatase 2A bindingGO:005172110.2MAPT, SLC6A3
6tau protein bindingGO:004815610.0APOE, SNCA
7protein homodimerization activityGO:00428038.9ACHE, APOE, CBS, LRRK2, MAPT, PARK7
8enzyme bindingGO:00198998.6APP, CBS, MAPT, PARK7, SNCA, TH
9identical protein bindingGO:00428028.5APOE, APP, CBS, LRRK2, MAPT, PARK7

Sources for Supranuclear Palsy, Progressive

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet